Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Insight Clinical Trials LLC

Neither a doctor nor a teaching hospital

Research payments

$4,157,017

397 payments

Through program year 2025, Insight Clinical Trials LLC is reported as receiving $4,157,017 in research payments, across 397 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $380,164 15
2024 Research $766,384 25
2023 Research $241,062 6
2022 Research $454,013 42
2021 Research $688,669 50
2020 Research $897,979 57
2019 Research $728,746 202

Breakdown

Who paid Research payments · program years 2019–2025
  1. Sage Therapeutics, Inc. $1,145,617 67 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $812,472 14 payments
  3. Eli Lilly and Company $764,997 13 payments
  4. Eisai Inc. $404,479 172 payments
  5. Otsuka Pharmaceutical Development & Commercialization, Inc. $395,955 13 payments
  6. ACADIA Pharmaceuticals Inc $215,068 31 payments
  7. BioXcel Therapeutics, Inc. $161,980 5 payments
  8. Neurocrine Biosciences, Inc. $107,657 59 payments
  9. Janssen Research & Development, LLC $48,984 1 payment
  10. Avanir Pharmaceuticals, Inc. $44,385 12 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment With Sage-217 in Adult Subjects With Major Depressive Disorder $618,999 47 payments
  2. Assessment of Safety, Tolerability and Efficacy of Ly3002813 Alone and in Combination With Ly3202626 in Early Symptomatic Alzheimers Disease $491,909 10 payments
  3. A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease $404,479 172 payments
  4. Connex-2 $317,587 1 payment
  5. A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment with SAGE-217 in Adult Subjects with Major Depressive Disorder $285,086 2 payments
  6. PoCC study in patients with PTSD $206,744 3 payments
  7. Bxcl501401 $161,980 5 payments
  8. A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Trial Evaluating the Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder (Trial 405-201-00014) $148,378 1 payment
  9. A Multi-Center, Randomized, Controlled Trial to Evaluate the Effectiveness of A Digital Therapeutic (CT-152) As Adjunctive Therapy in Adult Subjects Diagnosed With Major Depressive Disorder $142,597 3 payments
  10. A Study of Ly3202626 on Disease Progression in Participants With Mild Alzheimers Disease Dementia $138,270 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record